Clear Genetics' chatbot, named Gia, is an easy-to-use platform that guides patients throughout the genetic testing process and is currently being used by customers in Invitae's direct channel. Gia was ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae, a genetic testing services provider, reported Q1 2023 revenue of $117.4 million, down from Q1 2022's $123.7 million due to exited businesses and geographies. However, after accounting for ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

SAN FRANCISCO, March 15, 2023 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be ...

Shares of Invitae are trading for less than a nickel apiece after a report surfaced earlier this week claiming the genetic testing company is on the verge of filing for bankruptcy. The report came ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

SAN FRANCISCO, Dec. 20, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has completed a transaction with Integrated DNA Technologies, Inc. (IDT), ...